DI/GNOS
Your Knowledge Partner

OTCQB: DGNOF
TSXV : ADK
SOURCE : DIAGNOS Inc.

PRESS RELEASE

2025.02.05

DIAGNOS Announces Closing of Private Placement

Brossard, Quebec, Canada – February 5, 2025 – DIAGNOS Inc. ("DIAGNOS" or the "Corporation") (TSX Venture: ADK) (OTCQB: DGNOF), a pioneer in early detection of critical health issues through the use of Artificial Intelligence (*AI*) technologies, announces the closing, today, of a non-brokered private placement of 6,715,370 units (each a "Unit") issued at a price of $0.30 per Unit, for gross proceeds of $2,014,611 ("Private Placement").

Each Unit consists of:

- One (1) common share ("Share"), and

- One (1) common share warrant ("Warrant").

As part of the closing of the Private Placement, 6,715,370 Warrants have been issued to the subscribers. Each Warrant can be exercised to purchase one Share at a price of $0.40 per Share for a period of 18 months ending August 5, 2026.

In connection with the closing of the Private Placement, the Corporation (i) paid cash commissions totalling $39,246.72 and (ii) issued an aggregate number of 130,821 finder's warrants to five qualified firms acting at arm's length to the Corporation. Each finder's warrant entitles the holder to purchase one Share at an exercise price of $0.40 per Share for a period of 18 months ending August 5, 2026.

The net proceeds from the Private Placement will be used to fund product development and commercialization of AI-based screening services, regulatory affairs as well as general and administrative operations.

All securities issued as part of the Private Placement are subject to a statutory hold period ending June 6, 2025.

The closing of the Private Placement remains subject to receipt of all required approvals, including the approval of the TSX Venture Exchange, as well as execution of formal documentation.

All monies quoted in this press release shall be stated and paid in lawful money of Canada.

About DIAGNOS
DIAGNOS is a publicly traded Canadian corporation dedicated to early detection of critical health problems based on its FLAIRE Artificial Intelligence (AI) platform. FLAIRE allows for quick modifying and developing of applications such as CARA (Computer Assisted Retina Analysis). CARA's image enhancement algorithms provide sharper, clearer and easier-to-analyze retinal images. CARA is a cost-effective tool for real-time screening of large volumes of patients.

Additional information is available at www.diagnos.ca and www.sedarplus.com.

For further information, please contact:

Mr. André Larente, President
DIAGNOS Inc.
Tel: 450-678-8882 ext. 224
alarente@diagnos.ca

– 30 –